Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 10, 2001, Pages 1098-1105

  Moore, K H P ^a   Cass, L M ^a   Dallow, N ^a   Hardman, T C ^a   Jones, A ^a   Boyce, M ^a   Prince, W T ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLLAPSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INHIBITION KINETICS; MALAISE; MALE; NEUROTOXICITY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034823128     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012706     Document Type: Article

References (28)

1. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) - Initial phase I evaluation
2. GW420867X: A novel quinoxaline-class NNRTI of HIV-1 with improved antiretroviral properties in the presence of human serum and its components
3. NNRTI GW420867X: Comparative evaluation of the in vitro resistance profile
4. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors
5. HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type-1 that are targeted at the viral reverse transcriptase
6. Antiretroviral therapy for HIV infection: A review of current medications and therapies
7. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
8. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, the Netherlands, Canada and Australia Study
10. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed
11. Longer-term immunologic effects and side effects of successful antiretroviral therapy
12. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
13. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
14. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
15. Treatment of human immunodeficiency virus type 1 (HIV1)-infected cells with combination of HIV-1-specific inhibitors resuits in a different resistance pattern than does treatment with single-drug therapy
16. HIV-1 pharmacoresistance: Clinical and therapeutic implications
17. Sanctuary sites in HIV-1 infection
18. Adherence: A necessity for successful HIV combination therapy
19. Quantification of sleepiness: A new approach
20. The use of non-parametric methods in the statistical analysis of the two periods change-over design
21. Logarithmic transformation in bioequivalence: Application with two formulations of perphenazine
22. Assessment of dose proportionality: Report from statisticians in the pharmaceutical industry/pharmacokinetics UK Joint Working Party
23. Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in dog, cynomolgus monkey and mini-pig
24. The human hepatic cytochromes P450 involved in drug metabolism
25. CYP3A gene expression in human gut epithelium
26. Relative expression of cytochrome 450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics
27. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor
28. Preliminary tolerability, pharmacokinetics (PK) and initial effect on plasma HIV-1 RNA following administration of GW420867X once-daily (50mg, 100mg and 200mg) for 28 days to patients infected with HIV-1